Association Between Testosterone Replacement Therapy and the Incidence of DVT and Pulmonary Embolism: A Retrospective Cohort Study of the Veterans Administration Database

Chest

Volumn 150, Issue 3, 2016, Pages 563-571

  Sharma, Rishi ^a   Oni, Olurinde A ^a   Chen, Guoqing ^b   Sharma, Mukut ^a   Dawn, Buddhadeb ^b   Sharma, Ram ^a   Parashara, Deepak ^a   Savin, Virginia J ^a   Barua, Rajat S ^a   Gupta, Kamal ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

DVT; pulmonary embolism; testosterone replacement therapy

Indexed keywords

TESTOSTERONE; THROMBOXANE A2 RECEPTOR; WARFARIN; ANDROGEN;

ADULT; AGED; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; ERYTHROCYTOSIS; HUMAN; HYPERCOAGULABILITY; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; THROMBOCYTE AGGREGATION; VEIN THROMBOSIS; VETERANS HEALTH; FACTUAL DATABASE; GOVERNMENT; HORMONE SUBSTITUTION; HYPOGONADISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PULMONARY EMBOLISM; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOSIS; VETERAN;

AGED; ANDROGENS; COHORT STUDIES; DATABASES, FACTUAL; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; TESTOSTERONE; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VENOUS THROMBOSIS; VETERANS;

EID: 84995676348     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.05.007     Document Type: Article

References (42)

1. 1 Baillargeon, J., Urban, R.J., Ottenbacher, K.J., et al. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med 173:15 (2013), 1465–1466.
2. 2 Mohamoud, M.A., Chai, G., Staffa, J., Drug use review. Joint Meeting for Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management Advisory Committee (DSARM AC), 2014, US Food and Drug Administration, Silver Spring, MD http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM412536.pdf Published September 17, 2014. Accessed June 23, 2016.
3. 3 Shores, M.M., Smith, N.L., Forsberg, C.W., et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 97:6 (2012), 2050–2058.
4. 4 Basaria, S., Coviello, A.D., Travison, T.G., et al. Adverse events associated with testosterone administration. N Engl J Med 363:2 (2010), 109–122.
5. 5 Vigen, R., O'Donnell, C.I., Baron, A.E., et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 310:17 (2013), 1829–1836.
6. 6 Xu, L., Freeman, G., Cowling, B.J., et al. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med, 11, 2013, 108.
7. 7 Garnick, M.B., Testosterone replacement therapy faces FDA scrutiny. JAMA 313:6 (2015), 563–564.
8. 8 Grech, A., Breck, J., Heidelbaugh, J., Adverse effects of testosterone replacement therapy: an update on the evidence and controversy. Ther Adv Drug Saf 5:5 (2014), 190–200.
9. 9 Sharma, R., Oni, O.A., Gupta, K., et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J 36:40 (2015), 2706–2715.
10. 10 Glueck, C.J., Richardson-Royer, C., Schultz, R., et al. Testosterone therapy, thrombophilia-hypofibrinolysis, and hospitalization for deep venous thrombosis-pulmonary embolus: an exploratory, hypothesis-generating study. Clin Appl Thromb Hemost 20:3 (2014), 244–249.
11. 11 Glueck, C.J., Richardson-Royer, C., Schultz, R., et al. Testosterone, thrombophilia, and thrombosis. Clin Appl Thromb Hemost 20:1 (2014), 22–30.
12. 12 Baillargeon, J., Urban, R.J., Morgentaler, A., et al. Risk of venous thromboembolism in men receiving testosterone therapy. Mayo Clin Proc 90:8 (2015), 1038–1045.
13. 13 US Food and Drug Administration. FDA Adding General Warning to Testosterone Products About Potential for Venous Blood Clots. 2014, US Food and Drug Administration, Silver Spring, MD http://www.fda.gov/Drugs/DrugSafety/ucm401746.htm Published December 10, 2014. Accessed June 23, 2016.
14. 14 Health Canada. Summary Safety Review: Testosterone Replacement Products and Cardiovascular Risk. 2014, Health Canada, Ottawa, ON, Canada http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/testosterone-eng.php Published July 15, 2014. Accessed June 23, 2016.
15. 15 Lazarou, S., Reyes-Vallejo, L., Morgentaler, A., Wide variability in laboratory reference values for serum testosterone. J Sex Med 3:6 (2006), 1085–1089.
16. 16 Rosner, W., Auchus, R.J., Azziz, R., et al. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 92:2 (2007), 405–413.
17. 17 Wang, C., Catlin, D.H., Demers, L.M., et al. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 89:2 (2004), 534–543.
18. 18 Vesper, H.W., Botelho, J.C., Standardization of testosterone measurements in humans. J Steroid Biochem Mol Biol 121:3-5 (2010), 513–519.
19. 19 Bhasin, S., Cunningham, G.R., Hayes, F.J., et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95:6 (2010), 2536–2559.
20. 20 Robins, J.M., Hernan, M.A., Brumback, B., Marginal structural models and causal inference in epidemiology. Epidemiology 11:5 (2000), 550–560.
21. 21 Austin, P.C., An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46:3 (2011), 399–424.
22. 22 Harder, V.S., Stuart, E.A., Anthony, J.C., Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research. Psychol Methods 15:3 (2010), 234–249.
23. 23 Freedman, J., Glueck, C.J., Prince, M., et al. Testosterone, thrombophilia, thrombosis. Transl Res 165:5 (2015), 537–548.
24. 24 Glueck, C.J., Bowe, D., Valdez, A., et al. Thrombosis in three postmenopausal women receiving testosterone therapy for low libido. Womens Health (Lond Engl) 9:4 (2013), 405–410.
25. 25 Glueck, C.J., Freiberg, R.A., Wang, P., Heritable thrombophilia-hypofibrinolysis and osteonecrosis of the femoral head. Clin Orthop Relat Res 466:5 (2008), 1034–1040.
26. 26 Glueck, C.J., Friedman, J., Hafeez, A., et al. Testosterone, thrombophilia, thrombosis. Blood Coagul Fibrinolysis 25:7 (2014), 683–687.
27. 27 Fernandez-Balsells, M.M., Murad, M.H., Lane, M., et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 95:6 (2010), 2560–2575.
28. 28 Coviello, A.D., Kaplan, B., Lakshman, K.M., et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 93:3 (2008), 914–919.
29. 29 Pilo, R., Aharony, D., Raz, A., Testosterone potentiation of ionophore and ADP induced platelet aggregation: relationship to arachidonic acid metabolism. Thromb Haemost 46:2 (1981), 538–542.
30. 30 Johnson, M., Ramey, E., Ramwell, P.W., Androgen-mediated sensitivity in platelet aggregation. Am J Physiol 232:4 (1977), H381–H385.
31. 31 Rosenblum, W.I., el-Sabban, F., Nelson, G.H., et al. Effects in mice of testosterone and dihydrotestosterone on platelet aggregation in injured arterioles and ex vivo. Thromb Res 45:6 (1987), 719–728.
32. 32 Nakao, J., Change, W.C., Murota, S.I., et al. Testosterone inhibits prostacyclin production by rat aortic smooth muscle cells in culture. Atherosclerosis 39:2 (1981), 203–209.
33. 33 Gonzales, R.J., Ghaffari, A.A., Duckles, S.P., et al. Testosterone treatment increases thromboxane function in rat cerebral arteries. Am J Physiol Heart Circ Physiol 289:2 (2005), H578–585.
34. 34 Cembrano, J., Lillo, M., Val, J., et al. Influence of sex difference and hormones on elastine and collagen in the aorta of chickens. Circ Res 8 (1960), 527–529.
35. 35 Wolinsky, H., Effects of androgen treatment on the male rat aorta. J Clin Invest 51:10 (1972), 2552–2555.
36. 36 Greenberg, S., George, W.R., Kadowitz, P.J., et al. Androgen-induced enhancement of vascular reactivity. Can J Physiol Pharmacol 52:1 (1974), 14–22.
37. 2 receptor density and aggregation responses. Circulation 91:11 (1995), 2742–2747.
38. 38 Mooradian, A.D., Morley, J.E., Korenman, S.G., Biological actions of androgens. Endocr Rev 8:1 (1987), 1–28.
39. 39 Glueck, C.J., Goldenberg, N., Budhani, S., et al. Thrombotic events after starting exogenous testosterone in men with previously undiagnosed familial thrombophilia. Transl Res 158:4 (2011), 225–234.
40. 40 Cherrier, M.M., Matsumoto, A.M., Amory, J.K., et al. The role of aromatization in testosterone supplementation: effects on cognition in older men. Neurology 64:2 (2005), 290–296.
41. 41 Hulley, S., Grady, D., Bush, T., et al., Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:7 (1998), 605–613.
42. 42 Rossouw, J.E., Anderson, G.L., Prentice, R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:3 (2002), 321–333.